Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson gets FDA approval for generic pain drug
Watson’s oxycodone hydrochloride and ibuprofen product is the generic equivalent to Forest Laboratories’s Combunox, which is indicated for the short-term (not more than seven days) management of acute,
Watson’s oxycodone hydrochloride and ibuprofen product is the generic equivalent to Forest Laboratories’s Combunox, which is indicated for the short-term (not more than seven days) management of acute,
Pfizer said that Eraxis has been shown to be an effective new agent in the treatment of invasive candidiasis in a Phase III trial involving 47 trial sites
Under the terms of the grant, Modigene shall repay the Office of the Chief Scientist (OCS) the sum of the grant plus accrued interest through a series of
The granted claims of the patent include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the
The evaluation by the safety review committee was performed once the first cohort reached five weeks of treatment (two doses plus one week of follow-up). The safety data
Dosing has begun at Roswell Park Cancer Institute in Buffalo, New York, and will commence in the next several days at M.D. Anderson Cancer Center in Houston, Texas.
TPI-H-221 was a multi-center, randomized, double-blind, placebo-controlled study that enrolled approximately 260 subjects. This unique study was designed to determine the optimum treatment protocol based upon the immediate
Heart Health will enter into a consulting agreement with Systems Art Holding, to support the current product development and production of the Heart Health Monitor. The company intends
Mayo Clinic will enhance its current genetic testing services for thalassemia to include a new molecular diagnostic test based on multiplex ligation-dependent probe amplification (MLPA) and bead-based liquid
The agreement stems from the exclusive license to Amsterdam Molecular Therapeutics (AMT) from Digna Biotech to commercialize all gene therapy products resulting from the R&D activities performed at